Synonyms: JNT517
Compound class:
Synthetic organic
Comment: JNT-517 (Jnana Therapeutics) is an oral, allosteric inhibitor of SCL6A19-mediated phenylalanine reabsorption in the kidney. It is in clinical development for potential to treat phenylketonuria, an inherited metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. The chemical structure shown here was revealed during the First Time Disclosures session at the ACS meeting in September 2023, and we picked it up from Drug Hunter. Jnana Therapeutics have a patent that claims small molecule SCL6A19 inhibitors (WO2023122267A2), but this structure doesn't appear in that patent [1].
|
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05781399 | First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria | Phase 1 Interventional | Jnana Therapeutics |